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ABSTRACT: In the present work, to maintain a suitable blood level of vinpocetine (VP)
for a long period of time, VP-cyclodextrin-tartaric acid multicomponent complexes
were prepared and formulated in hydroxypropylmethylcellulose matrix tablets.
In vitro and in vivo performances of these formulations were investigated over a VP
immediate release dosage form. Solubility studies were performed to evaluate the drug
pH solubilization profile and to assess the effect of multicomponent complexation on VP
solubility. The drug release process was investigated using United States Pharmacopeia
apparatus 3 and a comparative oral pharmacokinetic study was subsequently under-
taken in rabbits. Solubility studies denoted the pH-solubility dependence of VP and
solubility improvement attained by complexation. Dissolution results showed controlled
and almost complete release behavior of VP over a 12-h period from complex hydro-
xypropylmethylcellulose-based formulations. A clear difference between the pharmaco-
kinetic patterns of VP immediate release and VP complex-based formulations was
revealed. The area under the plasma concentration-time curve after oral administration
of complex-based formulations was 2.1–2.9 times higher than that for VP immediate
release formulation. Furthermore, significant differences found formean residence time,
elimination half-life, and elimination rate constant values corroborated prolonged
release of VP from complex-based formulations. These results suggest that the oral
bioavailability of VP was significantly improved by both multicomponent complexation
and controlled release delivery strategies.  2007 Wiley-Liss, Inc. and the American
Pharmacists Association J Pharm Sci 96:2018–2028, 2007
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INTRODUCTION
Vinpocetine (VP) is a vincamine derivative that
has been used in clinical practice in Europe for
nearly three decades for the treatment of disorders
arising from cerebrovascular and cerebral degen-
erative diseases.1,2 VP is thought to increase the
cerebral flow in the ischemic areas of patients
with cerebrovascular disease, decrease platelet
aggregability in patients with transient ischemic
attack or stroke, increase red blow cell deform-
ability in stroke patients, and have neuroprotec-
tive abilities and a protective effect against brain
ischemia.3,4
VP is mainly used as immediate oral dosage
forms containing 5 mg of the active ingredient,
with a daily dosage regimen that can vary between
5mg 3/day to 20mg 3/day.5Unfortunately, the
very limited aqueous solubility and wettability of
VP can give rise to problems of both formulation
and low bioavailability (6.7%).6 Indeed, VP is a
poorly water-soluble base-type drug that presents
pH-dependent solubility. As the solubility and
dissolution relationships in the gastrointestinal
tract can be critical for the oral bioavailability of
poorly soluble weak bases as VP, because of the
possibility of drug precipitation upon entry into
the small intestine thatmayalso affect the amount
of drug available for uptake through the intestinal
mucosa,7 the use of cyclodextrin (CD) multicom-
ponent complexation with bCD, sulfobutyl ether
(SBE)bCD, tartaric acid (TA), and polyvinylpyrro-
lidone (PVP) has been attempted to overcome such
VP solubility and dissolution drawbacks.
One potential method of optimizing the efficacy
of drug activity is through the use of rationally
designed carriermaterials such asCDs. In thepast
decades, CD complexation has been extensively
applied to enhance the solubility, dissolution, and
bioavailability of poorly water-soluble drugs.
Therefore, the use of CDs as excipients in different
dosage forms has receivedmuch attention because
upon complex formation advantages such as im-
proved bioavailability, reduction of unwanted side
effects, or improved stability have often been
claimed. The improvement in absorption rate of
drugs administered in solid dosage forms has been
related to the increase in both solubility and
dissolution rates of the complexes as compared
with pure drug.8More recently, a concernwith the
amount of CDs in dosage forms due to toxicological
considerations, formulation bulk, and production
costs encouraged the development ofmethods that
could enhance the complexation efficiency of CDs,
by using a third additive such as water-soluble
polymers9,10 and hydroxy acids.11
In previous works, we have reported the com-
bined use of both bCDand SBEbCD,water-soluble
polymers [PVPandhydroxypropylmethylcellulose
(HPMC)], and hydroxy acids (TA) to improve VP
solubility.12,13 Considering that VP has an elim-
ination half-life of 2–6 h14 and requires chronic
administration, a controlled release dosage form
could provide increased clinical value over con-
ventional formulations, as a result of improved
therapeutic effect and patient compliance by re-
ducing dosing frequency, a more constant or
prolonged therapeutic effect, and possible en-
hanced bioavailability. Then, in an effort to reach
better dissolution properties as well as controlled
release rate of VP, we have prepared VP-CD-TA
multicomponent complexes and an optimal for-
mulation was subsequently designed by the com-
bination of these complexes into HPMC-based
hydrophilic tablet dosage forms (Ribeiro et al.,
submitted for publication).
Because dissolution rate of poorly soluble drugs
is a function of their water-solubility, enhance-
ment of drug solubility is expected to improve its
bioavailability. Recently, SBEbCD, a chemically
modified CD, became a more interesting option
than bCD to achieve complexation because of
better physicochemical properties and improved
inclusion behavior. Studies had proven that this
CDderivative is able to increasedrug oral bioavail-
ability.15,16 Thereby, the present studywas under-
taken to evaluate, by means of in vivo absorption
studies in the rabbit model, the feasibility of using
VP-bCD-TA and VP-SBEbCD-TA multicompo-
nent complexes in association with HPMC matrix
tablets as strategies to improve VP oral bioavail-
ability and also to obtain a prolonged therapeutic
effect of the drug as compared with an immediate
release formulation.
EXPERIMENTAL
Materials
VP was purchased from Covex (Madrid, Spain).
bCD [Kleptose1; molecular weight (MW) 1135]
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and (sulfobutyl ether)7M (SBE)bCD (Captisol
TM;
total degrees of substitution 6.8, MW 2160) were
kindly offered by Roquette (Lestrem, France) and
Cydex (Kansas City, MO). Polyvinylpyrrolidone
K30 (PVP) and TA were purchased from Sigma
Chemical Co. (St. Louis, MO). For the preparation
of the matrix tablets, Methocel1 HPMC K15M
CR (Dow Chemical, Midland, MI), monohydrate
lactose, and magnesium stearate of pharmaceuti-
cal grade were used. All solvents and chemicals
used were of high-performance liquid chromato-
graphy (HPLC) or analytical grade. Milli-Q water
was used to prepare buffer solutions and other
aqueous solutions used in this study.
Preparation of VP-CD-TA
Multicomponent Complexes
Solid multicomponent complexes, VP-bCD-TA
and VP-SBEbCD-TA, with and without PVP,
were prepared by the lyophilization method as
described in a previous work.12 Briefly, equimolar
amounts of CDs and VP were dissolved in water
and in 1.5% (w/v) TA solution, respectively. The
two solutions were sonicated for 15min andmixed
for 2 h at 508C. After filtration through a 0.45-mm
membrane filter (PVDF, Tracer1; Teknokroma,
Barcelona, Spain), the resulting clear solution
was frozen by immersion in an ethanol bath (Shell
Freezer, Labconco, Freezone1 model 79490) at
508C and then the frozen solution was lyophi-
lized in a freeze-dryer (Lyph-lock 6 apparatus;
Labconco) for 72 h. In the case of VP-CD-TA-PVP
multicomponent complexes, equimolar amounts
of CDs and VP were respectively dissolved in
0.25% (w/v) PVP and in 1.5% (w/v) TA solution.
The resulting solution was mixed and sonicated
for 15 min and then heated in an autoclave at
1208C for 20 min. After an equilibrium period of
72 h at room temperature, the resulting solution
was filtrated through a 0.45-mm membrane filter
and clear solution was frozen by immersion in an
ethanol bath at 508C, and subsequently lyophi-
lized in a freeze-dryer for 72 h.
VP Solubility Studies
The pH solubilization profile of VP was deter-
mined in the pH range found in physiological
fasted conditions of the human gastrointestinal
tract. The buffer solutions used for the pH solubi-
lization profile were the simulated gastric fluid
without enzymes, pH 1.2 [United States Pharma-
copeia (USP) XXV], 0.05 M phosphate buffer,
pH 4.5 (European Pharmacopeia, 4th ed.), 0.05 M
phosphate buffer, pH 6.0 (European Pharmaco-
peia, 4th ed.), simulated intestinal fluid without
enzymes, pH 6.8 (USP XXV), and 0.05 M phos-
phate buffer, pH 8.0 (European Pharmacopeia,
4th ed.). VP solubility studies were conducted by
the shake-flask method. Briefly, an excess of VP
was added to glass flasks containing 5 mL of each
buffer solution described above. The glass flasks
were sealed and mechanically stirred at ambient
temperature (22 18C) for 48 h. The pH of the
samples was checked periodically during the
experiment to ensure maintenance of buffer pH
values. All resulting suspensions were filtered
through a 0.45-mm membrane filter (La-Pha-
Pack1; Langerwehe, Germany) and VP concentra-
tions analyzed spectrophotometrically (UV-1603;
Shimadzu, Japan) at 316 nm. All experiments
were performed in triplicate.
VP aqueous solubility was evaluated in com-
plexed and uncomplexed forms. Samples were
prepared in triplicate by adding 5 mL of deionized
water and excess of solid powders into 20-mL
glass flasks which were sealed and mechanically
stirred at ambient temperature for 48 h. Result-
ing suspensions were filtered through a 0.45-mm
membrane filter and VP concentrations analyzed
spectrophotometrically at 316 nm.
Preparation of HPMC Matrix Tablets
HPMCmatrix tablets were manufactured by direct
compression of the formulation mixtures pre-
sented in Table 1 under a pressure of 1000 (F-A)
and 4000 kg/cm2 (F-B to F-D). The respective
powders (VP, multicomponent complexes, HPMC
K15 M CR, lactose, and magnesium stearate)
were blended thoroughly with a mortar and a
pestle. Formulation mixtures were weighed and
fed manually into the die of an instrumented
single-punch tablet press (Specac Ltd., Kent, UK)
fitted with 8-mm flat-faced punches. The tablet
weight was kept constant, at 200 and 300 mg for
the formulations incorporating pure drug or bCD
and SBEbCD multicomponent complexes, respec-
tively, by adjusting the amount of lactose used
in each formula. The weight variation of tablet
formulations is due to MW differences of both
CDs, because SBEbCD has a MW of 2160, a signi-
ficantly higher value than that of bCD (MW 1135).
All tablet formulations contained 20 mg of VP or
its equivalent.
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In Vitro Dissolution Testing
Dissolution tests were performed using USP
apparatus 3 (Bio-Dis III extended release tester,
VankelTM, Cary, NC), with a pH gradient method,
to simulate the conditions of the fasted human
gastrointestinal tract. Buffer solutions used for
dissolution testing were the same as described
above. The pH of the dissolutionmedia and corres-
ponding dissolution durations were set as follow:
pH 1.2 for 1 h, pH 4.5 for 0.5 h, pH 6.0 for 2.5 h,
and pH 6.8 for 8 h. The pH values and residence
times in each row were selected on the basis of
literature information of the pH values found
in different parts of the human gastrointestinal
tract in the fasted state.17–20 Dissolution testing
was performed at 37 0.28C. The vessels were
fitted with 250 mL of media and tablet formula-
tions, corresponding to 20 mg of VP, were placed
in the dipping tubes which contained a polypro-
pylene bottom screen of 420-mm mesh size. The
mesh size of the top screens was also fixed at
420 mm. A standard dip rate of 15 per minute was
used and dipping tubes were drained for 1 min
before moving to the following media. Sample
solutions (3 mL) were collected at specified time
intervals from dissolution vessels, using a plastic
syringe coupled with a polypropylene tube, which
was inserted inside the vessel, and an equal volume
of fresh test medium was replaced. Samples were
filtered through membrane filters of 0.45-mm pore
size (La-Pha-Pack1, Langerwehe, Germany) and
analyzed for UV absorption (UV-1603; Shimadzu,
Kyoto, Japan) at 316 nm. The cumulative percent
of drug released was calculated according to
calibration curves for each pH buffer solution
and a correction was applied for the cumulative
dilution caused by replacement of the sample with
an equal volume of freshmedium. All experiments
were made in triplicate.
Fit factors (f1 and f2) were used for comparing
the dissolution patterns because they are very
popular methods used to compare dissolution
profile data and are recommended for use in a
number of FDA guidance documents.21 For curves
to be considered similar, f1 value should be close to
0 and f2 value to 100. Generally, f1 values15 and
f2 values 50, which means an average difference
of no more than 10% at the sample time points,
ensures equivalence of the curves and thus of the
performance of the test and reference products.22
In Vivo Study Design
In vivo study was designed as a two-way rando-
mized crossover study, with 2 weeks’ dosing
interval, with a single oral dosing administration
(in six male New Zealand rabbits with an average
weight of 3.3 kg) to minimize any residual or
cumulative effects of the preceding dose. The
study was approved by the local Committee of
Laboratory Animal Care from the University
Hospital of Coimbra in accordance with the rules
and guidelines concerning the care and use of
laboratory animals. Rabbits were housed indivi-
dually in cages under environmentally controlled
conditions, on a 12-h light/dark cycle, and were
given free access to food and water. The day before
each experiment, rabbits were fasted for 14–16 h
and provided water ad libitum. They were cathe-
terized in the marginal ear vein for blood sampling
before drug administration. All rabbits received
two tablet formulations corresponding to 40 mg of
VP as a single dose. The relatively high dose was
needed to ensure blood levels appropriate for
analytical detection and pharmacokinetic anal-
ysis.15 Tablet formulations were administered
orally by gently compelling the opening of the
rabbit mouth and depressing of the tongue with
pincers. Tablets were swallowed intact by push-
ing them to the back of the pharynx with a flexible
gastric tube. After tablet administration, approxi-
mately 10 mL of water was given orally with a
syringe to facilitate swallowing and to prevent the
tablet from sticking to the rabbit throat. Serial
Table 1. Composition of VP Tablet Formulations
Formulation
Complex or
Pure VP (mg) HPMC (mg) Lactose (mg) Mg Stearate (mg) Total Weight (mg)
F-Aa 20.0 — 178.0 2.0 200.0
F-Bb 99.6 60.0 38.4 2.0 200.0
F-Cb 158.2 90.0 48.8 3.0 300.0
F-Db 120.6 90.0 86.4 3.0 300.0
aImmediate release formulation of VP.
bHPMC-based matrix tablet formulations of VP: B) VP-bCD-TA, C) VP-SBEbCD-TA, D) VP-SBEbCD-TA-PVP, multicomponent
complexes.
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blood samples (1.2–1.5 mL) were drawn from the
marginal ear vein before drug administration and
at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after drug
administration, to spiked ethylenediaminetetraa-
cetic acid tubes to prevent clotting and centri-
fuged (3500 rpm/15 min) immediately to obtain
plasma. Plasma samples were then stored at
208C until analysis.
Determination of VP Plasma Levels
Frozen samples were allowed to thaw at room
temperature. Rabbit plasma (0.5 mL), test sample
or free plasma spiked with known amounts of VP,
along with 50 mL of 0.35 mg/mL hydroxyprogester-
one acetate solution [internal standard, (IS)],
were deproteinized by the addition of 1.5 mL of
acetonitrile following vortex mixing at high speed
for 30 s and centrifugation for 10min at 5300 rpm.
The clear supernatant was transferred to a new
glass tube having 150 mL of 1 N hydroxide sodium
solution. After equilibrating, 3.5 mL of n-hexane
was added and the extraction was performed by
vortex mixing for 1 min. The tubes were centri-
fuged (5300 rpm/3 min) and the organic layer was
transferred to another set of clean tubes to be
back-extracted with 1.5 mL of 0.05 N sulfuric acid
solution (vortex mixing for 1 min). Tubes were
centrifuged (5300 rpm/3 min), the organic layer
was discarded and the aqueous phase transferred
to a clean tube containing 100 mL of 1 N hydroxide
sodium solution and back-extracted with 3.5 mL
of n-hexane. After mixing (1 min) and centrifu-
ging (5300 rpm/3 min), the organic phase was
recovered to a clean tube to be evaporated to
dryness at 408C under vacuum. The dried residue
was reconstituted with 120 mL of mobile phase
and 100 mL was injected into the chromatographic
system. The extraction efficiency of VP was deter-
mined by comparing the peak height of extracted
samples to those of nonprocessed quality control
(QC) samples at three different concentration
levels of 10, 50, and 100 ng/mL (n¼ 5) and was
found to be in the range of 90.7–98.3%.
Drug concentration levels were determined
using a reversed-phase HPLC method. Briefly,
quantitative analysis was performed on an HPLC
chromatograph (model 1050; Hewlett-Packard)
equipped with an injection valve of 20-mL sample
loop (model 7125; Rheodyne, Cotati, CA), a stati-
onary phase of LiChrospher 100 RP18 (250
4.6 mm, 5 mm; Merck, Darmsdadt, Germany)
fitted with a LiChrospher RP18 guard column
(4 4 mm, 5 mm; Merck). The mobile phase con-
sisted of a mixture of acetonitrile–0.01 M sodium
phosphate buffer solution containing 5 mM
heptane-1-sulfonic acid sodium, and 0.2% (v/v)
triethylamine, for which pH was adjusted to 5.5
with 1% (v/v) phosphoric acid solution (55:45).
Themobile phasewasdegassedbypassing through
a 0.45-mm membrane filter (PVDF, Tracer1,
Teknokroma) before use. The volume injected
was 100 mL which was eluted isocratically with a
flow rate of 1.0 mL/min at 308C, with detection
performed with ultraviolet absorption at a wave-
length of 230 nm. The extraction and HPLC
method resulted in symmetrical peak shape and
good baseline resolution for both VP and IS, with
retention times of approximately 8.5 and 10.3min,
respectively.
Stock solutions (0.1 mg/mL) of VP and IS were
prepared by dissolution in acetonitrile and kept at
48C. Standard solutions (n¼ 4) of VP in human
plasma (5, 10, 25, 50, 100, and 150 ng/mL) were
prepared daily from stock solutions by spiking the
suitable volume of various working solutions
diluted in the mobile phase and extracted and
analyzed as described above. Peak height ratios of
each VP to IS were measured and the calibration
curves of three consecutive days were obtained
from the least-squares linear regression. The
average regression line was used to calculate the
respective concentrations of VP in the plasma
samples. The linearity of detector response was
assessed for extracted plasma standards over the
range of 5–150 ng/mL. The calibration curve of VP
exhibited an excellent linearity and a correlation
coefficient of 0.9989.
The intra-day precision of the method (coeffi-
cient of variation) was assessed, on a single day,
by extracting and analyzing free plasma spiked
with known amounts of VP appropriate working
solutions yielding concentrations of 10, 50, and
100 ng/mL (QC samples, n¼ 5). The intra-day
precision was 6.3% (10 ng/mL), 3.4% (50 ng/mL),
and 1.5% (100 ng/mL). The inter-day precision
(coefficient of variation) was determined for the
sameQCsamples (n¼ 5) on three consecutive days
and was found to be 7.2% (10 ng/mL), 3.9% (50 ng/
mL), and 2.1% (100 ng/mL). Accuracy, expressed
as the mean % [(mean measured concentration)/
(theoretical concentration)] 100, was determin-
ed simultaneously as intra- and inter-day preci-
sion in the sameQCsamples (n¼ 5). Themeasured
values varied between 97.4–104.5% (intra-day)
and 93.1–106.2% (inter-day). These results con-
firmed the precision and accuracy of the method.
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Pharmacokinetics and Statistical Data Analysis
The pharmacokinetic parameters extracted from
the plasma data were calculated using noncom-
partmental analysis (WinNonlin1, version 1.1)
and included the maximum plasma concentration
(Cmax), the time to reach the maximum plasma
concentration (tmax), the whole area under the
drug plasma concentration-time curve (AUC0–1),
the mean residence time (MRT), the elimination
half-life (t1/2), and elimination rate constant (lz).
The relative bioavailability of formulations B, C,
and D was calculated taking as reference for-
mulation A, through the ratio of the respective
AUC0–1 values. Data are presented as mean
values standard deviation.
Statistical analysis of the pharmacokinetic para-
meters (Cmax, tmax, t1/2,MRT, lz, andAUC0–1) was
performed using GraphPad Prism1 version 4.0
software, by one-way analysis of variance and
followed by Tukey’s post test for multiple compar-
ison analysis. A value of p 0.05 defined the
statistical equivalence.
RESULTS AND DISCUSSION
VP Solubility Studies
Solubility and pH-solubility profiles are particu-
larly useful means of identifying compounds
likely to have absorption and distribution pro-
blems,23 especially if drugs present pKa values in
the physiological range, because the apparent
solubility may change greatly with changes in pH
of the environment.18 Because the rate and extent
of drug release from most controlled release
systems are influenced by the pH of the dissolu-
tion medium for drugs with pH-dependent solu-
bility and this dependency of drug release on pH
may lead to additional inter and intra-subject
variability in drug absorption,24 VP solubility was
examined as a function of pH over the range
typically encountered under fasted physiological
conditions of the human gastrointestinal tract.
In the pH range studied (1.2–8.0), VP showed
an approximately linear relationship between
the logarithm of the solubility and pH (Fig. 1).
Over this range, the solubility was significantly
enhanced by a reduction in pH, as expected,
because of the weak base character (pKa¼ 7.31)
of the drug and a drastic decreased solubility was
observed with higher pH values. Indeed, the
estimated solubility values for each pH solution
studied were 24.16 0.04 mg/mL at pH 1.2,
199.14 4.49 mg/mL at pH 4.5, 24.23 0.25 mg/
mL at pH 6.0, 5.38 0.53 mg/mL at pH 6.8, and
1.39 0.15 mg/mL at pH 8.0. Hence, VP solubility
was increased by a factor of approximately 17,400
considering both extreme pH values tested.
The solubility studies reported clearly illustrate
the impact of pH on VP solubility and dissolution.
From the solubility values obtained, it is predict-
able that the extent of VP dissolution in the gastric
environment will be high. Oppositely, under the
pH values generally found in the upper regions
of the gastrointestinal tract, the solubility and
dissolution of pure VP will not be sufficient for
complete dissolution of the doses habitually
administered. However, it is expected that this
drawback may be overcome by multicomponent
complexation of VP with CDs and TA, because
resulting complexes have demonstrated to have
better solubility and dissolution performances in
simulated intestinal fluid (pH 6.8) (Ribeiro et al.,
submitted for publication).
VP solubility measurements in deionized water
are schematically represented in Figure 2. As
Figure 1. VP pH solubilization profile in the pH
range of 1.2–8.0. Each point represents mean values
SD.
Figure 2. VP aqueous solubility obtained from the
uncomplexed form and lyophilized multicomponent
complexes. Results are presented as mean values.
ORAL BIOAVAILABILITY OF VINPOCETINE 2023
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 96, NO. 8, AUGUST 2007
expected from previous work,13 VP solubility in
multicomponent form was found to be higher than
pure VP. In fact, VP solubility in uncomplexed
form (&5 mg/mL) increased to approximately
80 mg/mL in VP-SBEbCD-TA-PVP multicompo-
nent complex, which corresponds to a 16,000-fold-
higher increase on VP aqueous solubility. The
improved VP solubility observed as a consequence
of multicomponent complexation was greater for
VP-SBEbCD-TA lyophilized complexes compared
with VP-bCD-TA lyophilized complex, clearly
denoting the superior solubilizationand complexa-
tion efficiency of SBEbCD. In addition, solubility
improvement of VP may be associated with the
high energetic amorphous state after complexa-
tion in VP from VP-SBEbCD-TA lyophilized com-
plexes as confirmedpreviously byX-ray diffraction
studies performed.12
In Vitro Dissolution Testing
In vitro dissolution testing serves as an impor-
tant tool for characterizing the biopharmaceutical
quality of a product at different stages in its
life cycle. In early drug development, in vitro
dissolution properties are supportive for choosing
between different alternative formulation candi-
dates for further development and for evaluation
of active ingredients.25 The therapeutic benefit of
a number of drugs administered in a traditional
dosage form is sometimes limited by physiological
barriers, undesirable physiochemical drug prop-
erties, or issues of drug toxicology. In such cases,
the development of drug delivery systems that
produce a modified in vivo drug release is a com-
mon research aim. By manipulating the release of
drugs from its dosage form, such restrictions may
be overcome and an improvement in therapeutic
effect observed.26 The present in vitro dissolution
study was designed to theoretically investigate
the influence of drug release properties from
immediate and controlled release formulations,
the dissolution of the different dosage forms, and
the release performance of drug particles from
multicomponent complexes through the hydrated
gel layer of HPMC tablet formulations.
The release profiles of VP from an immediate
release formulation (A) and from hydrophilic
HPMC-based matrix formulations (B, C, D) are
presented in Figure 3. Because of the basic nature
of VP, the release of the drug from formulation A
was immediate in the first hour of the dissolution
testing (pH 1.2) and thus there was no more VP
available to proceed on the following steps of
the dissolution experiment. Based on previous
solubility studies, a drastic decrease was expected
on VP solubility and dissolution at higher pH
values; therefore, multicomponent complexation
was attempted to improve the dissolution perfor-
mance of the drug over a pH range that simulates
the one found in the fasted gastrointestinal tract.
Hence, hydrophilic HPMC-based matrix formu-
lationsB,C, andD, containing the drug in the form
of VP-CD-TA multicomponent complexes, were
designed to overcome the VP solubility drawback
at higher pH values and to extend drug release
for a longer period of time without the risk of
precipitation. The dissolution profiles of these
formulations clearly indicated a controlled release
pattern over 12 h of the experiment, because
HPMC tablet formulations swelled upon contact
with the dissolution media and a gel layer was
formed on their surface. This gel retarded further
ingress of fluid and subsequent drug release.
Nevertheless, drug release was nearly complete
in the end of the dissolution experiment, almost
certainly because of higher solubility and disso-
lution performances of VP after multicomponent
complexation. Consequently, there existed a clear
difference in the in vitro drug release character-
istics of hydrophilic HPMC-based matrix formula-
tions B, C, and D as compared with VP immediate
release formulationA,which in turn,was expected
to provide a different in vivo drug release.
The results of the mathematical comparison of
hydrophilic HPMC-based matrix formulations B,
C, andD, byapplying f1 and f2 fit factors, revealed a
convergence of the dissolution profiles of these
formulations (Table 2) and demonstrated the
Figure 3. Dissolution profiles of the immediate
release formulation (F-A) and multicomponent com-
plex-based HPMC matrix formulations (F-B, F-C, and
F-D) of VP. Each point represents mean valuesSD.
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equivalence of in vitro performances of formula-
tions containing VP-bCD-TA, VP-SBEbCD-TA,
and VP-SBEbCD-TA-PVP multicomponent com-
plexes (f1 15 and f2 50). This fact may have
relevant pharmaceutical usefulness, in the case
of formulation C and D containing respectively
VP-SBEbCD-TA and VP-SBEbCD-TA-PVP multi-
component complexes, because the latter complex
incorporates a higher amount of VP, due to the
enhanced complexation efficiency of SBEbCD
toward VP in the presence of PVP, and conse-
quently a decrease of approximately 13% of
SBEbCD in the solid dosage form.12,13,27
Pharmacokinetics and Bioavailability Studies
The mean VP plasma concentrations obtained
after a single oral dose administration of the dif-
ferent formulations were plotted versus time in
Figure 4 and related pharmacokinetic parameters
are presented in Table 3. The absorption of VP
from the immediate release formulation (F-A) was
rapid reaching the maximum plasma level of
61.52 ng/mL after 2 h. VP in this formulation
showed a relatively high elimination half-life
(6.38 h) when compared with the reported value
of 2.33 h in humans,6 which can be due to the high
administered dose of the drug, but that is in
the limit value of 2–6 h reported by Wichert and
Rohdewald.14 However, when compared with
hydrophilic HPMC-based matrix formulations B,
C, and D, the levels of VP plasma from formula-
tion A decreased quickly. This rapid decrease was
probably caused by a decrease of absorption at
the intestinal level because of the lack of the
drug in its dissolved form, which is strongly
influenced by the pH in the intestine.28 No statis-
tical differences in the time values to reach the
maximum plasma concentration between VP im-
mediate release formulation (F-A) and HPMC-
based matrix formulations (F-B, F-C, and F-D)
formulated with multicomponent complexes could
be observed (p> 0.05). Nevertheless, extended
release patterns were evident for the absorption
of VP from the latter formulations. This is likely
due to the slow release rate of VP under a pro-
longed period through the hydrated gel of the
HPMC-based matrix formulations. Therefore,
despite the initial rapid increase in plasma level
of VP from hydrophilic HPMC-based matrix for-
mulations, a relatively constant plasma level was
Table 3. Mean (SD) Pharmacokinetic Parameters and Relative Bioavailability of VP (40 mg) in Six Rabbits, after
the Oral Administration of VP Immediate Release Formulation (F-A) or Hydrophilic HPMC-Based Matrix
Formulations Containing VP Multicomponent Complexes (F-B, F-C, and F-D)
Formulation Cmax (ng/mL) tmax (h)
AUC0-1
(ng h/mL) t1/2 (h) lz (h1) MRT (h)
Relative
Bioavailability (%)
F-Aa 61.52 10.54 2.0 518.35 76.47 6.38 1.41 0.1130 0.0227 9.74 2.76 —
F-Bb 50.90 6.18 1.5 1086.37 248.69 15.46 4.44 0.0484 0.0156 23.02 6.74 209.58
F-Cc 64.17 5.10 2.0 1416.26 236.92 14.67 3.55 0.0497 0.0131 21.86 5.25 273.22
F-Dd 71.19 6.81 2.5 1499.89 150.69 14.85 2.11 0.0475 0.0069 22.01 3.19 289.96
aImmediate release formulation containing pure VP.
bControlled release formulation containing VP-bCD-TA multicomponent complex.
cControlled release formulation containing VP-SBEbCD-TA multicomponent complex.
dControlled release formulation containing VP-SBEbCD-TA-PVP multicomponent complex.
Figure 4. VP plasma concentration-time profiles
after oral administration of VP immediate release
formulation (F-A) or hydrophilic HPMC-based matrix
formulations containing VPmulticomponent complexes
(F-B: VP-bCD-TA, F-C: VP-SBEbCD-TA, and F-D: VP-
SBEbCD-TA-PVP). Each point represents mean values.
Table 2. Fit Factor Values Obtained for Formulations
B, C, and D
Fit Factor F-C/F-Ba F-C/F-Da F-B/F-Db
f1 8.4 4.5 4.1
f2 58.3 72.0 63.0
aTaking formulation C as reference.
bTaking formulation B as reference.
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maintained for a longer time, reflecting the
in vitro release characteristics.
Despite similar in vitro release profiles of VP
from formulations B, C, and D, the in vivo study
revealed differences in the values of Cmax between
the formulations. Indeed, the Cmax value obtained
for formulation B was significantly lower than the
ones obtained for formulations C (p< 0.05) and D
(p< 0.001); this difference was probably related to
the distinct solubility performances of bCD and
SBEbCD complexes, discussed previously. Con-
versely, MRT, t1/2, and lz values were comparable
for all three formulations (p> 0.05) and signifi-
cantly different from the same parameters of
formulation A (p< 0.001). Formulations B, C,
and D produced a 2.2- to 2.4-fold increase in MRT
values compared with formulation A, clearly
suggesting a longer maintenance of VP in plasma
and hence prolonged release in the rabbit model.
Upon comparing t1/2 values, we found that for
controlled release matrices, the values were more
than double those for the immediate release
formulation (F-A). Because t1/2 values should be
similar for the same substance, the differences
encountered here are due to a prolonged absorp-
tion phase in the controlled release matrix for-
mulations (F-B, F-C, and F-D), where there is a
prolonged continuous introduction of VP into the
bloodstream.29
Compared with the VP immediate release
formulation (F-A), the administration of all hydro-
philic HPMC-based matrix formulations in-
creased the AUC0–1 values of VP, reflecting a
greater systemic exposure and, consequently,
higher oral bioavailability of the drug. The ratio
of mean AUC0–1 ranged from 2.1 to 2.9 and the
difference in AUC0–1 values between the formu-
lations was found to be statistically different
(p< 0.001). The more than twofold increase in
themeanAUC0–1values of formulationsB,C, and
D, was afforded by a greater VP aqueous solubility
and dissolution rate from multicomponent com-
plexes. In turn, this made possible the design and
use of controlled release solid dosage forms, with
smaller risk of drug precipitation in the upper
regions of the gastrointestinal tract, and, conse-
quently, in association to HPMC-based matrix
formulations, a maintenance of a more constant
VP blood level.
In corroboration with our previous in vitro
results, there was no significant difference be-
tween AUC0–1 values of formulations C and D
(p> 0.05) and therefore similar oral bioavailability
in rabbits was observed with both formulations.
These formulations were obtained respectively
with VP-SBEbCD-TA and VP-SBEbCD-TA-PVP
multicomponent complexes. In the latter complex,
PVP increased the solubility and complexation
efficiency of SBEbCD toward VP and as a result
the amount of SBEbCD in solid dosage forms was
reduced approximately 13%.13 Such observation
suggests the possibility of decreasing the amount
of CDs in solid dosage forms, by the addition of
water-soluble polymers to the aqueous complexa-
tion media, thereby contributing to the reduction
of formulation bulks, toxicity, and costs with CDs,
without injury of their pharmaceutical potential,
as previously stated by other authors.30
Significantly higher AUC0–1 values were
obtainedwithboth formulationsCandDrelatively
to formulation B. The differences stated reflect
the same trend observed for Cmax values for these
formulations and hence are probably related to
different solubility and efficiency complexation
performances ofVP observedwith bothCDs. Thus,
the use of VP-SBEbCD-TA multicomponent com-
plexes in the design of controlled release solid
dosage forms seems to be a better approach than
that of VP-bCD-TA multicomponent complexes.
CONCLUSIONS
The present study demonstrates the suitability of
the combined CD multicomponent complexation
and controlled release delivery strategies to im-
prove and maintain the oral absorption of VP for a
longer period of time.
Solubility is an important property that influ-
ences drug liberation and absorption and hence
has an important role in drug bioavailability,
because for a drug to be absorbed it must be
present in the form of an aqueous solution in
the absorption site.31 Therefore, in an effort to
achieve better solubility and dissolution proper-
ties through all regions of the gastrointestinal
tract, controlled release rate, as well as improved
oral bioavailability of VP, we have prepared VP-
CD-TA multicomponent complexes and then opti-
mal formulations were designed by the com-
bination of these complexes into HPMC-based
hydrophilic tablet dosage forms. A comparative
in vitro dissolution study of the resulting formula-
tions with an immediate release formulation of
the drug clearly showed controlled and almost
complete release behavior of VP over a 12-h period
in the case of HPMC formulations. Conversely,
complete dissolution of VP was observed for the
2026 RIBEIRO ET AL.
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immediate release formulation in the first hour of
the dissolution experiment, because of the basic
nature and pH-solubility dependence of the drug.
Further biopharmaceutics studies demon-
strated that controlled release multicomponent
complex-based formulations could dramatically
improve VP bioavailability over an immediate
release formulation, after oral administration in
rabbits. The lower oral bioavailability of VP from
the immediate release formulation was attributed
to poor solubility at intestinal pH, leading to pre-
cipitation of the drug from the dosage form,
followed by a slow process of dissolution and hence
a limiting step for absorption.However, increasing
the solubility of drug such as through multi-
component complexation with CDs and hydroxy
acids, as used in the present study, ensured better
VP dissolution in the upper regions of the gastro-
intestinal tract and resulted in higher extent of
bioavailability. Furthermore, the administration
of these multicomponent complexes assisted by
their formulation in HPMC matrix tablets re-
sulted in the maintenance of higher plasma drug
levels, thus supporting that not only multicom-
ponent complexes but also additional properties
of the carrier material may be responsible for the
controlled release and improved oral bioavail-
ability of VP.
The use of experimental animals such as
rabbits is common to predict pharmacokinetic
parameters of drugs administered by the oral
route in humans.16,32–34 Although VP solubility
and dissolution studies were performed in condi-
tions that intended to simulate the pH range found
in physiological conditions of the human fasted
gastrointestinal tract and in vivo studies were
performed in the rabbit model, we believe that
interspecies comparisons with humans are feasi-
ble because the pH values found in the gastro-
intestinal tract of rabbit vary between 1.9 in the
stomach to 6.0–8.0 in the intestine.35 Considering
the relatively high pKa value of VP (7.31), such
differences should not reflect an important varia-
bility of VP dissolved in the different regions of the
gastrointestinal tract in both species.
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